Generic drum debarments
Executive Summary
Denial of hearings and final debarment orders issued for Charles DiCola, former VP-operations at Bolar Pharmaceutical; Liaquat Hossain, former manager of product development at Superpharm; and Daphne Pai, former VP-regulatory affairs & quality control at American Therapeutics, a Nov. 5 Federal Register notice states. In separate requests for hearings, the plaintiffs argued that debarment violated the ex post facto clause of the U.S. Constitution. FDA maintains that since the intent behind section 306(a) (2) of the FD&C act is remedial, rather than punitive, debarment does not violate the ex post facto clause of the fourth.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth